MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Portfolio Pulse from
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) has announced the selection of The Centre for Human Drug Research in the Netherlands for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. The trial will begin recruitment in Q1 2025, with initial results expected in the second half of 2025.
November 20, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals is advancing to a clinical-stage company with the selection of a trial site for its novel ketamine analog, Ketamir-2. This marks a significant step in its development pipeline, potentially impacting its stock positively.
The announcement of a clinical trial site for Ketamir-2 indicates progress in MIRA's drug development, which is a positive signal for investors. The move to a clinical-stage company can enhance investor confidence and potentially lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100